Takeda clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14
What changed in the last 30 days
29 trials changed in the last 30 days: 1 stopped, 9 with notable changes, 19 with minor changes only.
- Notable: Fazirsiran and if Fazirsiran Can Help · Alpha-1 Antitrypsin Liver Disease Enrollment increased: 31 → 200 participants
- Minor: Zasocitinib · Psoriatic Arthritis Who Have Not Taken Biologic Medicines Enrollment closed, study ongoing
- Minor: Survey of Lanadelumab · Hereditary Angioedema Trial completed
- Minor: MARIBEL · Maribavir · Post-transplant Cytomegalovirus (CMV) Infection in Belgium Trial completed
- Minor: Continuation Study of Zasocitinib · Psoriatic Arthritis Trial sites expanded: 78 → 111 locations
- Notable: OBIZUR · Acquired Hemophilia A (AHA) in South Korea Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2028
- Minor: Lanadelumab in Teenagers and · Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia Trial completed
- Notable: Mezagitamab · Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant Recruitment opened
- Minor: ELRiSE MDS · Elritercept With Epoetin Alfa · Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Trial sites expanded: 162 → 166 locations
- Minor: ELRISE MF · Elritercept to Placebo · Myelofibrosis and Anemia Who Are Taking Ruxolitinib Trial sites expanded: 195 → 214 locations
- Notable: TAK-279 · Generalized Pustular Psoriasis or Erythrodermic Psoriasis Results posted: Nov 4, 2026
- Notable: Zasocitinib · Hidradenitis Suppurativa Primary completion moved earlier from Feb 22, 2028 to Feb 5, 2027
- Minor: Mezagitamab · Kidney Condition Called IgA Nephropathy Trial sites expanded: 179 → 186 locations
- Minor: Zasocitinib · Non-pustular Palmoplantar Psoriasis Start date pushed from Nov 1, 2026 to Nov 16, 2026
- Minor: Zasocitinib · Nonsegmental Vitiligo Primary completion moved earlier from Oct 12, 2027 to Mar 26, 2027
- Notable: MarsLight-11 · TAK-928 With Docetaxel · Non-Small Cell Lung Cancer Enrollment increased: 600 → 1200 participants
- Minor: TAK-861 · Narcolepsy With Cataplexy Primary and study completion pushed from Oct 2, 2026 to Dec 17, 2026
- Minor: HYPNOS · Epidemiology of Narcolepsy Type 1 and Type 2 in Spain Primary and study completion pushed from Sep 30, 2026 to Dec 31, 2026
- Minor: TAK-788 · Non-Small Cell Lung Cancer Trial completed
- Minor: TAK-360 · Narcolepsy or Idiopathic Hypersomnia Trial sites expanded: 24 → 31 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-29 | NCT07903220 A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 2 | |
| Phase 1/2 | 4 | |
| Phase 2 | 19 | |
| Phase 2/3 | 3 | |
| Phase 3 | 41 | |
| Phase 4 | 7 |
Not charted: 46 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 19
Crohn's Disease (14) · Ulcerative Colitis (10) · Psoriasis (7) · Colorectal Cancer (5) · Lung Cancer (5) · Non-Small Cell Lung Cancer (NSCLC) (5) · Hodgkin Lymphoma (4) · Multiple Myeloma (4) · Myelodysplastic Syndromes (MDS) (4) · Psoriatic Arthritis (4)
Get alerts when Takeda's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.